Skip to content
Markets
SPY773.09▲ +0.53%QQQ725.20▲ +1.05%DIA527.70▲ +0.64%GLD378.95▲ +0.34%TLT80.24▲ +0.14%BABA104.41▼ -3.87%NIO3.36▼ -2.04%PDD78.72▼ -3.56%Realtime derived data
Octans ResearchOCTANS RESEARCHWaitlist
Traders beneath the quotation boards on the floor of the New York Stock Exchange, 1963.
Source: Thomas J. O'Halloran, U.S. News & World Report (Library of Congress), public domain, via Wikimedia Commons

Medpace quarterly revenue rises 8.5% to $716.0 million

Medpace's revenue growth has more than halved. Results for the quarter ended September 30, 2026, from the earnings release filed with the SEC on Oct 21, 2026.

Octans ResearchPublished

Snapshot

Medpace's revenue growth has more than halved: revenue rose 8.5% to $716.0 million in the quarter ended September 30, 2026, from $659.9 million a year earlier, after 17.2% year over year growth the quarter before.

Coverage
Independent Research
Prepared by
Octans Research
Tickers
MEDP
As of

Market Data

Latest prices for the companies covered in this article
Company1D %Price
($MEDP)▲ +6.43%662.48

as of 16:00 ET · Realtime derived data

What We Know

Revenue for the quarter ended September 30, 2026 was $716.0 million, versus $659.9 million in the same quarter a year earlier, up 8.5%. That is its highest quarterly revenue of the last eight quarters. Diluted earnings per share was $4.84, up from $3.86.

Bar chart: Medpace: revenue, last eight quarters. US$ millions by fiscal quarter end, as of Oct 21, 2026. Dec 2024 536.6; Mar 2025 558.6; Jun 2025 603.3; Sep 2025 659.9; Dec 2025 708.5; Mar 2026 706.6; Jun 2026 707.3; Sep 2026 716.0. Latest quarter $716.0M, Up 8.5% vs a year earlier.
Source: SEC EDGAR (earnings release and XBRL financial data)

Quarterly revenue by fiscal quarter end, oldest first: Dec 2024: $536.6 million; Mar 2025: $558.6 million; Jun 2025: $603.3 million; Sep 2025: $659.9 million; Dec 2025: $708.5 million; Mar 2026: $706.6 million; Jun 2026: $707.3 million; Sep 2026: $716.0 million.

Octans View

Year over year revenue change by quarter, computed from the filed figures: Dec 2025 up 32.0%; Mar 2026 up 26.5%; Jun 2026 up 17.2%; Sep 2026 up 8.5%. On those figures, Medpace's revenue growth has more than halved. That read compares the latest two year over year growth rates and nothing else.

Bear Case · Room for Disagreement

This brief covers reported revenue and diluted earnings per share only. It does not cover guidance, margins, segment results, cash flow or the earnings call, and it makes no forecast. Revenue is the total on the release line we matched; a company's own adjusted measures can differ.

Method and source. Octans Research matched the revenue line in the earnings release (Exhibit 99.1) to the year ago quarter the company reported in its own XBRL financial data; the two must agree before anything is published. The quarterly history comes from the same XBRL data. The text is generated from those verified figures by a fixed template; no model wrote it.

Chart

$MEDP adjusted close, last 6 months $MEDP adjusted close, last 6 months: series rising from 411 to 662 (+61.4%) from 2026-04-24 to 2026-10-21. Scale 400 to 700. 400500600700 2026-04-242026-10-21 $MEDP ADJUSTED CLOSE, LAST 6 MONTHS +61.4% 662.5
Source: Tiingo · As of 2026-10-21Indicative, not investment advice.

Sources

  1. [1]SEC EDGAR — Medpace earnings release for the quarter ended September 30, 2026 (Exhibit 99.1), filed Oct 21, 2026
  2. [2]SEC EDGAR — Medpace XBRL financial data (company facts)

These are the sources this piece was drafted from. How we verify. Found an error? Tell us and we correct it in public.

$716.0M

Revenue for the quarter ended September 30, 2026 was $716.0 million, versus $659.9 million in t… · What we know

Related coverage

More on $MEDP

4 reports